La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
54 hedge funds and large institutions have $70.9M invested in La Jolla Pharmaceutical Company in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 22 reducing their positions, and 14 closing their positions.
39% more call options, than puts
Call options by funds: $158K | Put options by funds: $114K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less capital invested
Capital invested by funds: $78.6M → $70.9M (-$7.65M)
13% less funds holding
Funds holding: 62 → 54 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
59% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.07M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$190K |
| 3 |
Renaissance Technologies
New York
|
+$182K |
| 4 |
BlackRock
New York
|
+$161K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.04M |
| 2 |
Morgan Stanley
New York
|
-$608K |
| 3 |
Goldman Sachs
New York
|
-$406K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$311K |
| 5 |
JP Morgan Chase
New York
|
-$284K |
LJPC Hedge Fund Activity: Q3 2021 in Review
54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2021, worth a combined $70.9M — down 9.7% from $78.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LJPC and 6 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 9 added.
The largest buyer was HealthInvest Partners, opening a new position worth an estimated $1.07M. The largest seller was Millennium Management, cutting an estimated $1.04M.
- 54 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2021, down from 62 in Q2 2021.
- Funds reported $70.9M of La Jolla Pharmaceutical Company stock for Q3 2021, down 9.7% quarter-over-quarter.
- 6 funds opened new La Jolla Pharmaceutical Company positions in Q3 2021 and 14 closed out, a net change of -8 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q3 2021 was HealthInvest Partners, an estimated $1.07M added.
- The largest La Jolla Pharmaceutical Company seller in Q3 2021 was Millennium Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2021.